{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:47:19Z","timestamp":1777355239523,"version":"3.51.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with inborn errors of immunity (IEI) have increased\u00a0risk of developing cancers secondary to impaired anti-tumor immunity. Treatment of patients with IEI and cancer is challenging as chemotherapy can exacerbate infectious susceptibility. However, the literature on optimal cancer treatment in the setting of IEI is sparse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We present a patient with specific antibody deficiency with normal immunoglobins (SADNI), immune dysregulation (ID), and stage III ovarian carcinoma as an example of the need to modify conventional treatment in the context of malignancy, IEI, and ongoing infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective chart review of the patient\u2019s clinical manifestations, laboratory evaluation and treatment course.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our patient is a female with SADNI and ID diagnosed with stage III ovarian carcinoma at 60 years of age. Her ID accounted for antinuclear antibody positive (ANA+) mixed connective tissue diseases, polyarthralgia, autoimmune neutropenia, asthma, autoimmune thyroiditis, and Celiac disease. Due to the lack of precedent in the literature, her treatment was modified with continuous input from infectious disease, allergy\/immunology and oncology specialist using a multidisciplinary approach.<\/jats:p><jats:p>The patient completed debulking surgery and 6 cycles of chemotherapy. The dosing for immunoglobulin replacement therapy was increased for prophylaxis. Chemotherapy doses were lowered for all cycles preemptively for IEI. The therapy included carboplatin, paclitaxel, bevacizumab, and pegfilgrastim. The patient completed six-months of maintenance medication involving bevacizumab.<\/jats:p><jats:p>Her treatment course was complicated by <jats:italic>Mycobacterium avium-complex<\/jats:italic> (MAC) infection, elevated bilirubin and liver enzymes attributed to excessive immunoglobulin replacement therapy, and urinary tract infection (UTI) and incontinence.<\/jats:p><jats:p>Cancer genetic analysis revealed no targetable markers and primary immunodeficiency gene panel of 407 genes by Invitae was unrevealing. Lab tests revealed no evidence of Epstein-Barr Virus (EBV) infection. Post-chemotherapy imaging revealed no evidence of cancer for 1 year and 4 months, but the disease relapsed subsequently. The patient\u2019s lung scarring requires vigilance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our patient with ovarian cancer and IEI required modified treatment and prevention of complications. In cases of IEI, optimal chemotherapy should be titrated to minimize immunosuppression yet treat cancer aggressively while decreasing the risk of infection with prophylactic antibiotics and prolonged post-treatment surveillance, including pulmonary evaluation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.843741","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T18:38:15Z","timestamp":1656527895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: Initial Treatment Adjustments and Complications in Ovarian Cancer Patient With Inborn Error of Immunity"],"prefix":"10.3389","volume":"12","author":[{"given":"Jamila","family":"Mammadova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Redden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boglarka","family":"Ujhazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumai","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryssa","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyra","family":"Gatewood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Duff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charurut","family":"Somboonwit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakrapol","family":"Sriaroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztian","family":"Csomos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Dasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Harville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roohi","family":"Ismail-Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolan E.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00365","article-title":"Cancers Related to Immunodeficiencies: Update and Perspectives","volume":"7","author":"Mortaz","year":"2016","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03135","article-title":"CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID","volume":"9","author":"Kralickova","year":"2019","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2017.06.009","article-title":"Intrinsic and Extrinsic Causes of Malignancies in Patients With Primary Immunodeficiency Disorders","volume":"141","author":"Hauck","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaci.2011.02.047","article-title":"Primary Immunodeficiency Diseases Associated With Increased Susceptibility to Viral Infections and Malignancies","volume":"127","author":"Rezaei","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B5","volume-title":"SEER Cancer Statistics Review, 1975-2018","author":"Howlader","year":"2020"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207768","article-title":"Recycling the Purpose of Old Drugs to Treat Ovarian Cancer","volume":"21","author":"Nunes","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP Inhibitor Resistance: The Underlying Mechanisms and Clinical Implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2021.05.012","article-title":"Risk of Pneumonitis in Cancer Patients Treated With PARP Inhibitors: A Meta-Analysis of Randomized Controlled Trials and a Pharmacovigilance Study of the FAERS Database","volume":"162","author":"Ma","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202004_20852","article-title":"Non-AIDS Defining Cancers: A Comprehensive Update on Diagnosis and Management","volume":"24","author":"Ceccarelli","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis613","article-title":"The Rising Challenge of non-AIDS-Defining Cancers in HIV-Infected Patients","volume":"55","author":"Deeken","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.10","article-title":"Pharmacotherapy in Cancer Patients With HIV\/AIDS","volume":"95","author":"Beumer","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-013-0166-8","article-title":"Non-AIDS-Defining Cancers Among HIV-Infected Patients","volume":"10","author":"Cutrell","year":"2013","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B14","article-title":"Mycobacterium Avium Intracellulare","volume-title":"StatPearls","author":"Akram","year":"2022"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/jmmcr.0.000935","article-title":"Recurrence of Pulmonary Mycobacterium Avium Complex Disease Due to Endogenous Reactivation","volume":"1","author":"Taga","year":"2014","journal-title":"JMM Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139251","article-title":"Experimental Reactivation of Pulmonary Mycobacterium Avium Complex Infection in a Modified Cornell-Like Murine Model","volume":"10","author":"Cha","year":"2015","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10020","article-title":"Intravenous Immunoglobulin-Associated Elevation of Liver Enzymes in Neurological Autoimmune Disorder: A Case Series","volume":"12","author":"Behera","year":"2020","journal-title":"Cureus"},{"key":"B18","article-title":"Development of Cancer in Patients With Primary Immunodeficiencies","volume":"28","author":"Salavoura","year":"2008","journal-title":"Anticancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ajh.21903","article-title":"Malignancies in the Setting of Primary Immunodeficiency: Implications for Hematologists\/Oncologists","volume":"86","author":"Shapiro","year":"2011","journal-title":"Am J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020451","article-title":"Common Variable Immunodeficiency and Gastric Malignancies","volume":"19","author":"Leone","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.04.045","article-title":"Doxycycline, Salinomycin, Monensin and Ivermectin Repositioned as Cancer Drugs","volume":"29","author":"Markowska","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2021.57.7.3235211","article-title":"Role of Nitazoxanide as a Repurposed Drug in the Treatment and Management of Various Diseases","volume":"57","author":"Bharti","year":"2021","journal-title":"Drugs Today (Barc)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2019.11.001","article-title":"Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt\/mTOR Signaling","volume":"359","author":"Zhang","year":"2020","journal-title":"Am J Med Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"}],"updated-by":[{"DOI":"10.3389\/fonc.2022.1007616","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.843741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T15:56:20Z","timestamp":1664207780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.843741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":24,"alternative-id":["10.3389\/fonc.2022.843741"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.843741","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fonc.2022.1007616","asserted-by":"object"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"article-number":"843741"}}